Adcetris

Producer: Takeda Pharma
contains
Adcetris is a means of immunotherapy (antibody).Active substances
Brentuximab vedotin
Application
Adcetris is used to treat certain forms of lymphoma (non-Hodgkin's lymphoma and cutaneous T-cell lymphoma, most commonly located in the skin).
Only used in hospitals.
Dosage
Available as a powder for concentrate for solution for infusion, after reconstitution and dilution, into a vein.
- Adults: Usually 1.8 mg per kg body weight (not more than 180 mg) every 3 weeks.
Note:
- In case of malnourished kidneys or liver, the dose should be reduced.
possible side effects
Very common (over 10%) | Fever, Reactions and Discomfort during Infusion, Fatigue, Weight Loss Diarrhea, Constipation, Nausea, Abdominal pain, Vomiting Cough, Spiritlessness Increased risk of infection due to lack of white blood cells Joint pain, Muscle pain Nervous inflammation, eg on the arms and legs Skin rash, skin rash Infections, respiratory infection |
Common (1-10%) | Chills Liver effect, Sponge in the mouth pneumonia Blood deficiency, increased tendency to bleeding due to decrease in platelets Elevated blood sugar Back pain Nervous system disorders, Dizziness Shingles, Hair loss |
Uncommon (0.1-1%) | Inflammation of the pancreas Destruction of the nerve around the nerve Severe skin reaction, Severe skin reaction where the skin is destroyed Anaphylactic shock - An acute severe allergic condition, Blood poisoning |
Unknown | Virus infection in the brain |
If the organism is unable to get rid of all the cells that Adcetris has broken, so-called tumor light can occur, which can lead to an abnormally high level of waste in the blood and possibly kidney failure. If side pain occurs or blood is present in the urine, it may be a sign of tumor light and in this case you should seek medical advice.
Pregnancy
Use only under certain conditions.- There is limited experience with the use of the agent for pregnant women. Should only be used in special cases after consultation with the specialist.
breastfeeding
Do not use this text. This text differs from the company's approved product information (product summary).Traffic
No warning.Blood donor
Do not drop. Donor must be declared by the donor village.effect
- Adcetris is a cell-inducing agent that is coupled to a carrier that leads the cell-killing agent to the cancer cells. Here, the cell-killing agent is released into the cancer cell, which prevents the cancer cell from dividing itself, after which it goes to the ground.
- The half life in the blood (T?) is 4-6 days.
Pharmaceutical forms
Powder for concentrate for solution for infusion. 1 vial contains 50 mg brentuximab vedotin.
Special warnings
- In case of a lack of white blood cells (tends to infect) or by nerve infection on eg arms and legs, the dose should be reduced.
- If psychological or neurological side effects occur, for example in the form of confusion, balance problems, visual disturbances, memory or speech problems, it may be a sign of serious and possibly fatal brain inflammation and you should contact your doctor immediately.
Using other medicines
It is important to inform your doctor about all the medicines you are taking.
- Concomitant use of bleomycin (cell killers) should be avoided due to increased risk of lung damage.
- Certain fungicides (eg itraconazole) may increase the effect of Adcetris and increase the risk of infection.
- Rifampicin (tuberculosis) may reduce the effect of Adcetris.
Grants, delivery, packages and prices
subsidies | extradition | Dispensing form and strength | Packing | Price in kr. |
May only be delivered to hospitals. Delivered according to the provisions for drugs in delivery group A | powder for concentrate for solution for infusion, opl.50 mg | 1 piece. | 30.848,10 |